Nuvectis Pharma (NVCT) Price & Analysis

Compare

106 Followers

NVCT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.44 - $11.80

Previous CloseN/A

Volume31.37K

Average Volume (3M)178.95K

Market Cap

$174.38M

Enterprise Value$132.81M

Total Cash (Recent Filing)$26.79M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.72

Next Earnings

Nov 11, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding25,456,848

10 Day Avg. Volume70,577

30 Day Avg. Volume178,951

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue4.96

Enterprise Value/Gross Profit14.69

Enterprise Value/Ebitda-5.85

Forecast

1Y Price Target

$13.50

Price Target Upside103.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical DataNXP900's data has been promising, showing an ability to resensitize cancer cells to antitumor therapy, which could enhance treatment effectiveness.

Clinical DevelopmentPhase 1b initiation marks next step in NXP900's clinical development, indicating progress and potential for new treatment options.

Bears Say

Clinical ResultsFollowing disappointing results from NXP800's Phase 1 trial, management is now solely focused on its lead asset, NXP900 for lung cancer.

Stock PerformanceShares are trading down ~7% due to the NXP800 data being less than favorable, impacting market confidence negatively.

Nuvectis Pharma News

Nuvectis Pharma initiates NXP900 program

Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b program for NXP900. Published first on TheFly –...

18d ago

NVCT

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

Cash and cash equivalents were $26.8M vs. $18.5M as of December 31, 2024. CEO Ron Bentsur commented, “In...

24d ago

NVCT

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nuvectis Pharma (NVCT) to $10 from $15 and keeps a...

25d ago

NVCT

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

Nuvectis Pharma (NVCT) provided the final clinical data update from the Phase 1b study of NXP800 in recurrent,...

29d ago

NVCT

Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with...

23d ago

NVCT

Nuvectis Pharma Reports Q2 2025 Financial Results and Progress

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

NVCT

Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma, reducing the price target to...

25d ago

NVCT

Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Nuvectis Pharma, with...

28d ago

NVCT

Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating

Maxim Group analyst Naz Rahman has reiterated their bullish stance on NVCT stock, giving a Buy rating yesterday....

2M ago

NVCT

Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target...

2M ago

NVCT

Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer

Nuvectis Pharma (NVCT) announced the completion of a clinical DDI study in healthy volunteers for NXP900, supporting NXP900’s...

2M ago

NVCT

Nuvectis Pharma Approves Proposals at Annual Meeting

Nuvectis Pharma ( ($NVCT) ) just unveiled an update. On June 12, 2025, Nuvectis Pharma, Inc. held its...

3M ago

NVCT

Nuvectis Pharma Launches New $60M Stock Offering Program

Nuvectis Pharma ( ($NVCT) ) has issued an announcement. On May 9, 2025, Nuvectis Pharma announced the establishment...

4M ago

NVCT

Nuvectis Pharma Reports Q1 2025 Progress and Financials

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

NVCT

NVCT FAQ

What was Nuvectis Pharma, Inc.’s price range in the past 12 months?

Nuvectis Pharma, Inc. lowest stock price was $4.44 and its highest was $11.80 in the past 12 months.

What is Nuvectis Pharma, Inc.’s market cap?

Nuvectis Pharma, Inc.’s market cap is $174.38M.

When is Nuvectis Pharma, Inc.’s upcoming earnings report date?

Nuvectis Pharma, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 74 days.

How were Nuvectis Pharma, Inc.’s earnings last quarter?

Nuvectis Pharma, Inc. released its earnings results on Aug 05, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.252 by -$0.048.

Is Nuvectis Pharma, Inc. overvalued?

According to Wall Street analysts Nuvectis Pharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvectis Pharma, Inc. pay dividends?

Nuvectis Pharma, Inc. does not currently pay dividends.

What is Nuvectis Pharma, Inc.’s EPS estimate?

Nuvectis Pharma, Inc.’s EPS estimate is -0.25.

How many shares outstanding does Nuvectis Pharma, Inc. have?

Nuvectis Pharma, Inc. has 25,456,848 shares outstanding.

What happened to Nuvectis Pharma, Inc.’s price movement after its last earnings report?

Nuvectis Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.252. Following the earnings report the stock price went down -5.35%.

Which hedge fund is a major shareholder of Nuvectis Pharma, Inc.?

Currently, no hedge funds are holding shares in NVCT

Nuvectis Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-150.12%

Trailing 12-Months

Asset Growth

47.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma (NVCT) Earnings & Revenues

Historic Earnings Reports

NVCT Stock 12 Month Forecast

Average Price Target

$13.50

▲(103.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.584615384615384,8.36923076923077,9.153846153846153,9.938461538461539,10.723076923076922,11.507692307692308,12.292307692307691,13.076923076923077,13.861538461538462,14.646153846153846,15.43076923076923,16.215384615384615,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.315384615384615,7.8307692307692305,8.346153846153847,8.861538461538462,9.376923076923077,9.892307692307693,10.407692307692308,10.923076923076923,11.438461538461539,11.953846153846154,12.46923076923077,12.984615384615385,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.046153846153846,7.292307692307692,7.538461538461538,7.7846153846153845,8.03076923076923,8.276923076923076,8.523076923076923,8.76923076923077,9.015384615384615,9.26153846153846,9.507692307692308,9.753846153846155,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.19,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.69,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >